INCAGN01876: Clinical Trials

7 trials of INCAGN01876, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed, 1 terminated, 1 unknown. 6 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 2, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 14Completed 2, Active not recruiting 1, Terminated 1

Follow INCAGN01876: new trials by email Literature Review of INCAGN01876 trials Research Report on INCAGN01876

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
INCAGN01876, retifanlimab - Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies
Phase 2WithdrawnIncyte Biosciences International Sàrl2023-03-012023-09-15
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
INCAGN01876, INCMGA00012, DPV-001 - Cancer of the Head and Neck
Phase 1Active not recruitingProvidence Health & Services192021-08-052026-09-03
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
INCMGA00012, INCAGN01876, SRS - Glioblastoma
Phase 2Active not recruitingUniversity of Pennsylvania392020-06-232026-06-23
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
INCAGN01876, Epacadostat, Pembrolizumab - Advanced Malignancies, Metastatic Cancer
Phase 1 / Phase 2TerminatedIncyte Biosciences International Sàrl102017-11-212021-07-22
Biomarker-based Study in R/M SCCHN
Afatinib, Palbociclib, standard of care - Carcinoma, Squamous Cell of Head and Neck
Phase 2UnknownEuropean Organisation for Research and Treatment of Cancer - EORTC3402017-11-162023-11-03
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
INCAGN01876, Nivolumab, Ipilimumab - Advanced Malignancies, Metastatic Cancer
Phase 1 / Phase 2CompletedIncyte Biosciences International Sàrl1452017-04-252025-08-14
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
INCAGN01876 - Advanced Malignancies, Metastatic Cancer
Phase 1 / Phase 2CompletedIncyte Biosciences International Sàrl1002016-06-202021-02-26

Conditions studied

Squamous Cell Carcinoma of Head and Neck (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Carcinoma, Renal Cell (3)  ·  Melanoma (3)  ·  Neoplasm Metastasis (3)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma, Merkel Cell (2)  ·  Carcinoma, Transitional Cell (2)  ·  Endometrial Neoplasms (2)  ·  Mesothelioma (2)  ·  Ovarian Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Stomach Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Uterine Cervical Neoplasms (2)

Sponsors

Incyte Biosciences International Sàrl (4)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Providence Health & Services (1)  ·  University of Pennsylvania (1)

Countries

United States (6)  ·  Belgium (2)  ·  Spain (2)  ·  Australia (1)  ·  France (1)  ·  Italy (1)  ·  United Kingdom (1)

Top investigators

John E. Janik, MD (1)  ·  John Janik, MD (1)  ·  John N. Janik, MD (1)  ·  Nawel Bourayou, MD (1)  ·  Stephen Bagley, MD, MSCE (1)

Results publications

PMID 30307465, PMID 40711469

NIH funding

2016 (1), 2017 (1)